8legs: Moderna

Your Followed Topics

#1 out of 42.8M est. views

In a phase 2 trial, the personalized mRNA melanoma vaccine added to pembrolizumab cut the five-year recurrence risk in high-risk, surgically resected melanoma.
About 70% of patients in the vaccine group remained cancer-free at five years, compared with about 49% on standard therapy, suggesting meaningful benefit when paired with pembolizumab.
Combining the vaccine with Keytruda reduced the risk of metastasis by about 60%, indicating stronger systemic control of cancer spread.

Vote 22

#2 out of 4

Vaccine development is active for Bundibugyo Ebola as new outbreaks raise concerns in DR Congo and Uganda.
IAVI is adapting its vaccine approach to fight Bundibugyo during the ongoing outbreak.
Moderna uses mRNA technology to target Bundibugyo Ebola as part of the response.
Oxford is developing a new vaccine platform with trials expected in two to three months.
Cepi funds early-stage research to accelerate vaccine development.
Experts warn every day counts as the outbreak grows in the region.
MSF cautions the situation is deeply alarming as cases rise quickly.
Vaccine development targets Bundibugyo, a less common Ebola species with limited vaccines.
No licensed Bundibugyo vaccine exists yet as the outbreak expands.
The outbreak in DR Congo has triggered international attention and funding.

Vote 0

#3 out of 4

health22h ago

CEPI pledged up to $50 million to Moderna for preclinical work and Phase 1 testing of its BDBV mRNA vaccine.
CEPI will also fund other groups to develop vaccines using similar platforms against Bundibugyo.
The Bundibugyo outbreak in the DRC fuels urgency for vaccines specific to this strain.
Moderna’s vaccine leverages its mRNA platform to enable rapid development for emerging threats.
CEPI’s broader funding supports vaccine development efforts alongside Moderna.
No licensed therapeutics exist specifically for Bundibugyo yet.
Outbreak conditions include armed conflict and large population movement in the DRC.
WHO reports over 1,000 cases and more than 200 deaths in the Bundibugyo outbreak.
CEPI’s funding also supports vaccine development at Oxford and Serum Institute of India.
Two licensed Ebola vaccines currently target the Zaire strain, not Bundibugyo.

Vote 0

#4 out of 473.0K est. views

health15h ago

Survivors in Congo recount fighting the Bundibugyo Ebola strain as the outbreak expands across eastern provinces.
Health authorities report hundreds of confirmed cases, with most in Ituri’s eastern region.
WHO and partners commit funds to accelerate development of three experimental vaccines.
Frontline workers who recovered describe monitoring patients and the moment of testing negative.
Officials emphasize rapid detection, isolation, and strict infection control as key barriers.
Uganda closes its border and monitors cases to limit cross-border spread.
GOV officials highlight vaccine development as a priority amid ongoing trials.
WHO acknowledges progress and delivers support despite security and mistrust challenges.
New Ebola treatment center opens in Bunia to improve patient care.
Experts attribute recoveries to initiating care early in dedicated health facilities.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.